Navigation Links
Saladax Biomedical, Inc. Appoints Mark D. Myslinski as Chief Commercial Officer
Date:11/16/2012

BETHLEHEM, Pa., Nov. 16, 2012 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, announced today that Mark D. Myslinski has been appointed senior vice president and chief commercial officer of the company.

Mr. Myslinski has nearly 30 years of life sciences and diagnostics industry experience with Fortune 100 and venture-backed startup organizations.  He was recently president and CEO of RedPath Integrated Pathology, Inc. where he and the team transformed the company from a research and market development focus to full commercialization of a novel molecular diagnostic assay in a Clinical Laboratory Improvements Amendments (CLIA) certified laboratory.

"Mark's extensive experience in diagnostics and his leadership within the life science community will be invaluable to Saladax as the company targets new markets for the commercialization of its MyCare assays," said Kevin Harter, president and CEO of Saladax.  "In particular, Mark's expertise will be critical as Saladax pursues the formation of a laboratory that meets CLIA standards."

Previous to Mr. Myslinski's time at RedPath Integrated Pathology, Inc., he served as vice president of evidence-based medicine at Ortho Clinical Diagnostics, Inc. and general manager, molecular and cellular diagnostics division of Veridex, LLC, both of which are Johnson & Johnson companies.

"I'm excited to join Saladax during this time of rapid growth with the formation of a CLIA certified laboratory at the company's headquarters and the continued expansion of its MyCare assays worldwide," said Mr. Myslinski.  "Saladax's solutions offer patients a means of personalized chemotherapy treatment by finding the optimal dose for each individual patient. This is very important to clinical outcomes by assuring the right dosage gets delivered to the patient in the most efficient manner."

About Saladax Biomedical, Inc.
Saladax Biomedical develops novel diagnostic assays for the practical delivery of personalized medicine.  Our proprietary line of MyCare™ assays improves the efficacy of existing drugs by optimizing the dose administered for each individual patient.  Saladax's initial focus is oncology, with a portfolio of 13 chemotherapy drug assays in various stages of development.  Three MyCare assays, My5-FU™, MyPaclitaxel™ and MyDocetaxel™, are currently offered to the oncology community in markets around the world. 

The company's MyCare technology platform is broad and flexible, enabling wide application in many therapeutic categories.  This technology also enables Saladax to serve as a valuable partner to pharmaceutical and biotechnology companies in the development of companion diagnostics (CDx), addressing multiple risks and challenges encountered in drug development.

The company was founded in 2004 and is headquartered in Bethlehem, Pennsylvania.  Saladax is ISO 13485:2003 certified.

Saladax Biomedical, Inc.
Adrienne Choma, Esq.
Sr. VP & Chief Operating Officer
achoma@saladax.com

Media Contact:
Tiberend Strategic Advisors, Inc.
212-827-0020
Andrew Mielach
amielach@tiberend.com
or
Claire Sojda
csojda@tiberend.com

 


'/>"/>
SOURCE Saladax Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
2. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
3. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
4. Nephros Appoints John C. Houghton as President and Chief Executive Officer
5. Elsevier Appoints New President of Elsevier CPM Resource Center
6. GenWay Biotech Appoints New Vice President of Custom/OEM
7. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
8. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Hill-Rom Appoints Alton Shader President of Hill-Rom North America
11. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 http://www.researchandmarkets.com/research/fqx6nz/global_skin ) ... Skin Protective Equipment Market 2016-2020" report to ... ) has announced the addition of the ... to their offering. --> ... the addition of the "Global Skin Protective ...
(Date:2/8/2016)... , Feb. 8, 2016  A research team ... scientists has discovered details of how the abnormal breakage ... a particularly aggressive form of acute lymphoblastic leukemia (ALL). ... which genetic mutations trigger overproduction of immature cells, called ... The discoveries of the malfunction underlying the type called ...
(Date:2/8/2016)... -- As part of a major growth and expansion initiative, Dune ... Lori Chmura as President of Dune Inc., its U.S. ... extensive experience in the medical device space will play a ... --> --> In her ... marketing and operational functions in the U.S. She is tasked ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Stephanie Hebert Insurance Agency, serving families ... new charity campaign. As part of their ongoing community involvement program, funds are ... that children deserve a voice, and in the spirit of neighbors helping neighbors ...
(Date:2/8/2016)... ... 2016 , ... Tingley Rubber Corporation , a leading ... range of unique and advantaged protective solutions to a growing and dynamic ... customer service and marketing support. A new distribution center in Brampton, Ontario will ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... networking and relationship-marketing firm, announced today that nominations will be accepted February ... (ISE®) West Awards. , Awards include the Information Security Executive® of ...
(Date:2/8/2016)... ... 2016 , ... GrassrootsHealth published data from its D*action public ... in the GrassrootsHealth cohort with substantially higher vitamin D levels than a cohort ... states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits of vitamin ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... The ... annually in this country. The AutismOne 2016 Conference, which is being held May 25-29 ... often won’t hear elsewhere about helpful interventions and causes of chronic illness in children. ...
Breaking Medicine News(10 mins):